Roche to acquire Poseida (PSTX.US) for $1.5 billion, expected to close in Q1 next year

Poseida Therapeutics(PSTX.US), a leader in the clinical-stage allogeneic cell therapy and gene therapy fields, announced that it will be acquired by Roche for a total equity value of approximately $1.5 billion. The acquisition includes $9.00 in cash per share, plus untradeable or value rights (CVR) that could provide shareholders with an additional $4.00 in cash per share upon achievement of certain milestones. The entire transaction is expected to be completed in the first quarter of 2025. Poseida will continue to advance its non-viral CAR-T therapies and gene medicines as part of the Roche Pharmaceuticals division.

Since 2022, Poseida and Roche have collaborated to develop a ready-to-use CAR-T cell therapy for patients with hematologic malignancies. The acquisition not only marks Poseida's formal integration into the Roche Group but also signals deeper progress in the allogeneic cell therapy field for both parties.

Levi Garraway, Chief Medical Officer of Roche, said, "Building on the successful collaboration we have already established with Poseida, this acquisition is undoubtedly going to drive further breakthroughs in our allogeneic cell therapy efforts."

Dr. Kristin Yarema, President and CEO of Poseida, also expressed her anticipation for the collaboration: "We are thrilled to deepen our collaboration with Roche to advance our pipeline and future projects. Roche's global strength in late development and commercialization is undoubtedly going to help bring the translational potential of allo CAR-T to patients worldwide."

As of the time of writing, Poseida's premarket shares have risen over 222% to $9.22.